文献速递白血病

CD33剪接多态性决定初治急性髓系白血病对吉妥珠单抗奥唑米星的应答:来自儿童肿瘤协作组随机III期试验AAML0531的报告

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
PubMed 文献 · J Clin Oncol · 2017-06-23

基于儿童肿瘤协作组AAML0531随机III期试验,评估CD33剪接单核苷酸多态性rs12459419对含吉妥珠单抗奥唑米星(GO)化疗应答的影响。CC基因型患者中GO组较无GO组复发风险显著降低(26% vs 49%,P<.001),无病生存率更高(65% vs 46%,P=.004);CT或TT基因型患者中GO暴露未影响复发风险(39% vs 40%,P=.85)。作者认为CC基因型可能是选择GO显著应答患者的潜在生物标志物。

要点

  • rs12459419 T等位基因与更高的D2-CD33转录本水平及更低的诊断时白血病细胞表面CD33强度相关(均P<1.0E-6)。
  • CC基因型患者中,GO组较无GO组复发风险显著降低(26% vs 49%,P<.001),无病生存率更高(65% vs 46%,P=.004)。
  • CT或TT基因型患者中,GO暴露未影响复发风险(39% vs 40%,P=.85),GO附加获益未出现。

核心结论

  • 作者认为,rs12459419为CC基因型的患者对GO有显著应答,该基因型可能作为选择GO显著应答患者的潜在生物标志物。

研究设计与样本

  • 基于儿童肿瘤协作组AAML0531随机III期试验,评估初治急性髓系白血病患者的CD33剪接单核苷酸多态性。
  • 患者随机接受标准五疗程化疗 alone(无GO组,n=408)或化疗联合两剂GO(诱导期一次、强化期一次;GO组,n=408)。

主要发现

  • rs12459419基因型分布为CC 415例(51%)、CT 316例(39%)、TT 85例(10%),次要等位基因频率为30%。
  • T等位基因与更高的D2-CD33转录本水平显著相关(P<1.0E-6),并与更低的诊断时白血病细胞表面CD33强度显著相关(P<1.0E-6)。
  • CC基因型患者中,GO组较无GO组复发风险显著降低(26% vs 49%,P<.001)。
  • CT或TT基因型患者中,GO暴露未影响复发风险(39% vs 40%,P=.85)。
  • CC基因型患者中,GO组较无GO组无病生存率更高(65% vs 46%,P=.004);CT或TT基因型患者中未观察到GO附加的该获益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjugate, is a re-emerging therapy for acute myeloid leukemia (AML). CD33 single nucleotide polymorphism rs12459419 C>T in the splice enhancer region regulates the expression of an alternatively spliced CD33 isoform lacking exon2 (D2-CD33), thus eliminating the CD33 IgV domain, which is the antibody-binding site for GO, as well as diagnostic immunophenotypic panels. We aimed to determine the impact of the genotype of this splicing polymorphism in patients with AML treated with GO-containing chemotherapy. Patients and Methods CD33 splicing single nucleotide polymorphism was evaluated in newly diagnosed patients with AML randomly assigned to receive standard five-course chemotherapy alone (No-GO arm, n = 408) or chemotherapy with the addition of two doses of GO once during induction and once during intensification (GO arm, n = 408) as per the Children's Oncology Group AAML0531 trial. Results The rs12459419 genotype was CC in 415 patients (51%), CT in 316 patients (39%), and TT in 85 patients (10%), with a minor allele frequency of 30%. The T allele was significantly associated with higher levels of D2-CD33 transcript ( P < 1.0E-6) and with lower diagnostic leukemic cell surface CD33 intensity ( P < 1.0E-6). Patients with the CC genotype had significantly lower relapse risk in the GO arm than in the No-GO arm (26% v 49%; P < .001). However, in patients with the CT or TT genotype, exposure to GO did not influence relapse risk (39% v 40%; P = .85). Disease-free survival was higher in patients with the CC genotype in the GO arm than in the No-GO arm (65% v 46%, respectively; P = .004), but this benefit of GO addition was not seen in patients with the CT or TT genotype. Conclusion Our results suggest that patients with the CC genotype for rs12459419 have a substantial response to GO, making this a potential biomarker for the selection of patients with a likelihood of significant response to GO.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lamba JK, Chauhan L, Shin M, et al. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2017. PMID: 28644774. doi:10.1200/JCO.2016.71.2513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。